Table 4

Individual case description over time of athletes with myocardial involvement after infection with SARS-CoV-2

Athlete AAthlete BAthlete C*Athlete D
Age27212118
SexMaleMaleMaleMale
SARS-CoV-2 symptomsCoughFever and coughNasal congestion, muscle ache and tirednessNasal congestion, headache, loss of smell and taste
Cardiac symptomsNoneNonePalpitationsNone
Post-infection ECG abnormalitiesNoneNoneDecrease of T wave amplitude in lead II and aVF, and T-wave inversion in lead IIINew inferolateral T wave inversions
Infection to assessment interval5 months5 months1 month10 days
Initial cardiac MRI
LGEBasal to apical lateral myocardial and pericardialFocal pericardial/epicardial at inferolateral midventricular wall with pericardial effusion (PE)Basolateral to midventricular posterior epicardialPericardial/epicardial LGE at the inferolateral wall
Native T1 relaxation time (ms)939±63 msNA1232±101 msNA
Sports restrictionNoNo9 months1 month
LGE evolutionComplete resolution (8 and 18 months)Persisting LGE without PE (10 and 17 months)Persisting LGE without inflammation (15 months)Persisting LGE (3 and 9 months)
Return to sportsNo active myocardial inflammationNo active myocardial inflammationAfter resolution of symptoms, ECG abnormalities, myocardial inflammation (assessed by PET-CT) and normalisation of cardiac biomarkersAfter resolution of symptoms and ECG abnormalities and in the absence of elevated inflammatory markers
  • *The clinical course of this case, including LGE evolution, has been extensively described elsewhere.24

  • aVF, augmented vector foot; LGE, late gadolinium enhancement.